- COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS
-
The present invention relates to compounds and their use in the prophylactic and/or therapeutic treatment of pulmonary fibrosis and/or related conditions.
- -
-
Paragraph 00180; 00181
(2018/02/28)
-
- Synthesis and in vitro evaluation of botryllazine B analogues as a new class of inhibitor against human aldose reductase
-
Botryllazine B analogues of diverse substitution patterns have been prepared, and their in vitro inhibitory activities against recombinant human aldose reductase (h-ALR2) evaluated. Among the 15 compounds tested, 6-(4-aminophenyl)-2-(4-hydroxyphenyl)carbonylpyrazine (7b) proved to be the most potent inhibitor, with IC50=0.91 μM. Kinetic analyses of 7b and botryllazine B (1) revealed that these inhibitors exhibit an unprecedented mixed-type inhibition on h-ALR2 with respect to the substrate d,l-glyceraldehyde, in the presence of NADPH at inhibitor concentrations near the IC50 values.
- Saito, Ryota,Tokita, Mai,Uda, Keisuke,Ishikawa, Chikako,Satoh, Mitsutoshi
-
experimental part
p. 3019 - 3026
(2009/06/18)
-
- Pyrazole and Isoxazole Derivatives as New, Potent, and Selective 20-Hydroxy-5,8,11,14-eicosatetraenoic Acid Synthase Inhibitors
-
In a previous paper, we reported the N-hydroxyformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor. Despite its attraction as a potential therapeutic agent for cerebral diseases, the preparation of an injectable formulation
- Nakamura, Toshio,Sato, Masakazu,Kakinuma, Hiroyuki,Miyata, Noriyuki,Taniguchi, Kazuo,Bando, Kagumi,Koda, Ayumi,Kameo, Kazuya
-
p. 5416 - 5427
(2007/10/03)
-
- Phenylpyrazine derivatives and thrombolytic agent
-
Novel phenylpyrazine derivatives of the following general formula: STR1 (where R1 is a hydrogen atom, a halogen atom, a lower alkyl group, a lower alkoxy group or a hydroxyl group; and R2 is a halogen atom, a lower alkyl group, a low
- -
-
-